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expression, FA, and the presence and/or severity of Coronary Artery Disease (CAD). 
Methods: Patients, prospectively enrolled, had blood drawn and analyzed for: gene PMs 
(PCRIRFLP: t-PA. Alu repeat; urokinase, BamHI; PAI-1, Hindlll; fibrinogen, Haelll; 
MTHFR, Hinfl). plasma levels of FPs (ELISA: t-PA, PAI-1, u-PA). fibrinogen (clotting 
assay), FA (PAP assay), Lp(a) and homocysteine. The absence/presence and severity of 
CAD was determined by angiographic analyses; medical histories included risk factors. 
Data were analyzed by logistic regression, multivariate analysis and combined risk factor 
interactions. _ 
Results: Of the 1107 patients enrolled (57% male, 70% Caucasian, age 19.88 yrs), 465 
(21%) had no CAD. Factors associated with CAD presence were: U-PA PM, age, smok- 
ing, Lp(a), hypercholesterolemia. PAI- activity/antigen and a combined U-PA and fibrin- 
ogen PM interaction and gender/age interaction. Factors associated with CAD severity 
were: U-PA PM, age, smoking, hypercholesterolemla, diabetes, BMI, t-PA antigen. Lp(a) 
and a combined u-PA and fibrinogen PM interactton, u-PA and t-PA PM interaction, u-PA 
and MTHFR PM interaction and a gender/race Interaction. The u-PA PM, independently 
and/or in association with other FP PMs. was associated with plasma levels of FA, PAI- 
antigen/activity and fibrinogen, but not u-PA.Conclusions: 1) The u-PA PM appears to 
be associated with the development and progression of CAD; 2) A significant interaction 
exists between various FP PMs, particularly the u-PA PM, in determining plasma FP lev- 
els and FA; 3) Lack of association between the u-PA PM and plasma u-PA levels sug- 
gests that regulation of plaque-localized expression of u-PA is important. These results 
suggest a potential role for FPsiFA and FP gene interactions in the development and 
progression of CAD with age. 
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Background: Plasmlnogen activators inhibitor type 1 (PAI-1) is the most important regula- 
tory element in fibnnolytic system, and may be involved in the efficacy of fibrinolytic treat- 
ment for acute myocardial infarction (AMI). 
Aim: The study aimed lo elucidate the association between plasma PAI- antigen con- 
centration (PAS) and activity (PAct) before and after standard streptokinase (STK) infu- 
sion and clinical outcome in patients (pts) with AMI. 
Material and methods: The studied group consisted of 82 pts with AMI with ST elevation 
(aged 61.0+9.0 yrs. 26 females, 56 males) treated with STK. Plasma PAg and PAct were 
measured before, immediately after and 1,2,3,4,5 hours after STK infusion using com- 
mercially available ELISA tests (Biopool, Sweden). Clinical outcome (mortality, reperiu- 
slon and reocclusion rate) was analyzed during mean follow-up of 59 weeks (range I- 
96). Kaplan-Meier curves for overall survival (OS) and event-free survival (EFS) were 
calculated according to PAg concentration. 
Resulb: Peak increase in PAg and PAct was demonstrated after STK treatment in the 
3rd hour. Therefore, PAg and PAct at admission to hospital (PAgO. PActO) and 3 hours 
after STK (PAg3, PAct3) were further analyzed. PAg3 and PAct3 were significantly 
higher as compared to PAgO and PActO (30.0+13.3 vs. 20.8i8.6 ng/ml, p=O.O01 and 
37.3+13.7 vs. 10.0*11.2 IU/ml, p<O.OOOl, respectively). PAg3 values were increased in 
pts who died during follow-up (n=l5)(40.8*3.3 vs. 24.7i14.2 ng/ml, p=O.O38) and in pts 
without reperfuslon (36.5tll.4 vs. 20.3r12.6 @ml, p=O.O29). Threshold value of PAg3 
predictive for no repedusion, calculated using ROC curve analysis, were 21.8 ng/ml 
(sew. 77%, spec. 59%, area under the ROC curve 0.65) and for fatal outcome 33.3 ngl 
ml @ens. 90%, spec. 66%, area under the ROC curve 0.70). The probability of survival of 
pts with PAg3 over and below 33.3 ng/ml was 65% and 97% respectively (p=O.O0016). 
There was no significant difference in PActO and PAcl3 between groups separated con- 
cerning mortality, repedusion and reocclusion. 
Conclusions: Plasma PAI- antigen concentration over 33.3 nglml in the 3rd hour after 
fibrinolytlc treatment of AMI predicts unfavorable clinical outcome. 
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Thrombus formation and vascular smooth muscle cell (VSMC) proliferation are key 
events in the pathogenws of vascular diseases. Mediators from both platelets such as 
PDGF and the coagulation system such as thrombin can affect VSMC proliferation. 
Thus, we examined whether PDGF and thrombin interact at the level of VSM cell cycle 
regulation. When human saphenous vein VSMC were stimulated with a maximal concen- 
tration of thrombin (3 U/ml), no significant increase !n cell number was observed over 4 
days. In contrast, thrombin potentlated threshold concentrations of PDGF-BB (1 nglml) 
(increase in cell number: thrombin alone 4’375&‘105; PDGF alone 5’375i2’057; throm- 
bin plus PDGF 18‘688~1’711; p=n.s. for thrombin vs. PDGF; pcO.0002 for thrombin or 
PDGF vs. thrombln plus PDGF; n=4). SH-thymidine incorporation revealed that potentia- 
tion did also occur with ten times lower thrombin concentrations (n=6). Potentiation was 
prevented by hirudin (3 U/ml). Thrombin did not alter PDGF c( or p receptor expression 
as determined by FACS analysis. Thus, expression of cell cycle proteins regulating Gl 
progression was determined by Western blotting for up to 30 hours of mitogenlc stimula- 
tion. The cyclin-dependent kinase inhibitors ~21, ~27, and p57 were neither affected by 
thrombln nor PDGF alone. In contrast, thrombin plus PDGF caused p27 downregulatlon, 
while ~21 was slightly Induced. and p57 remained unaffected. Expression of cyclin- 
dependent kinase 2 (cdk2) and cyclln E was not affected under all these conditions. 
CdkP activity was neither affected by thrombin nor PDGF alone, but enhanced by throm- 
bin plus PDGF. This increase in cdk2 activity was prevented by hirudin. Inhibition of PI3 
kinase by LY294002 prevented p27 downregulatlon In response lo thrombin plus PDGF. 
Thrombin alone did not activate AkVPKB, while activation by PDGF alone was identical 
to that by PDGF plus thrombin. Thus, thrombin IS not mitogenlc for human saphenous 
vein VSMC, but strongly potentiates VSMC proliferation to PDGF in a dose-dependent 
manner. This potentiation is related to activation of PI3 kinase, and results in Akt/PKB 
independent downregulation of the CKI ~27. 
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Background: Tissue Factor (TF) and its inhibitor, the tissue factor pathway inhibitor 
(TFPI) probably play an Important role in the thrombogenicity of atherosclerotic plaques 
but the factors regulating their expression are poorly known. 
Methods TF,TFPI and activated factor VII (F Vlla) levels were measured in the athero- 
sclerotic plaques of 100 consecutive patients undergoing carotid endartereclomy. A mul- 
tiple linear regression model was used lo test the relationships between TF, TFPI and 
FVlla with 1) documented history of ischemic cerebral events (ICE), 2) conventional car- 
diovascular risk factors, 3) markers of inflammation (fibrinogen, interleukin-6, CRP) and 
coagulation activation (thrbmbin-antithrombin complexes, D-dimers) and metabolic syn- 
drom (Body mass index (BMI), insulinemia, triglyceridemia) and 4) plaque morphology 
(presence or absence of a massive lipid-rich core). 
Results : Plaque TF activity. TFPI antigen and FVlla were strongly correlated with each 
other. TF and TFPI but not FVlla were higher in the 40 symptomatic than In the 60 
asymptomatic patients (TF :1.82*0.32 vs 1.02*0.29 mlfigramme of plaque, median+ 
[95%CI]., p=O.O08 and TFPI :53.50*11.36 vs 20.6Oi7.92 pg/g, p=O.OOOl, respectively). 
The distribution of traditional cardiovascular risk factors was not different between 
asymptomatic and symptomatic subjects. TF activity was higher and TFPI was lower in 
men than in women. The plasma CRP level was a strong independent predictor for 
plaque TF activity. BM1>25 and maswe lipid rich core were positive predictors and 
hypertriglyceridemia was negative predictors for plaque TFPI. 
Conclusion : In carotid plaques, TF and TFPI levels were higher In patlents with a docu- 
mented history of ICE. TF is strongly related to the inflammatory process while TFPI is 
dependent of the presence of a massive lipid core and of markers of the metabolic syn- 
dram. 
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Background: Chemokines released by the endothelium have pro-aggregatory properties 
on platelets. Fractalkine, a recently dwovered membrane-bound chemokine with a 
transmembrane domain, is expressed in vascular injury, however, the effects of fractalk- 
Ine on platelets have not yet been investigated. 
Methods and Results: Blood was taken from healthy Wistar-Kyoto-rats and the expres- 
slon of the fractalkine-receptor on platelets was demonstrated. The modulation of sur- 
face-expression of P-selectin, a reliable marker of platelet activation, was assessed by 
flow cytometry. P-selectin expression was significantly enhanced by in vitro stimulation 
with recombinant rat fractalkine (FR: 60.4i7.7 mfu [mean fluorescence units]) as com- 
pared with baseline levels (BL: 21.6*2.9 mfu. p<O.OOl). Preincubation with either the 
nitric oxide-donor sodium nitroprusside (SNP) or the cyclooxygenase inhibitor acetyl sail- 
cylic acid (ASA) prevented the fractalkine-induced Increase in surface P-seledin expres- 
sion. Selectively inhibiting the function of recombinant fractalkine by an antagonizing 
antibody (anti-FR) or the dlsruption of the G-protein coupled intracellular signaling cas- 
cade of the fractalkine receptor by pertussis toxin (PTX) completely prevented fractalkine 
mediated platelet activation and adhesion (antl-FR: 15.2eO.9 mfu; PTX: 19.8e3.1 mfu, 
p<O.OOl vs. FR). 
In an adhesion flow chamber stimulation wth fractalkine significantly enhanced platelet 
adhesion to collagen and fibrinogen by 20% and 60% respectively. Similar to P-selectin 
expression, enhanced adhesion could be prevented by the antagonizing antibody or pre- 
incubation of platelets with PTX. 
Conclusion: The membrane-bound chemokine Induces platelet activation and adhesion. 
As fractalkine is overexpressed in atherosclerosis and vascular injury it IS likely to sub- 
stantially contribute to increased thrombogenesis in vascular diseases. 
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Background: Recent studies have demonstrated favorable effects of mlneralocorticoid 
receptor (MR) blockade in conditions associated with up-regulation of the renln-angio- 
tensin axls. We hypothesized that spironolactone modulates thrombotlc response to 
injuly in a genetlc model of hyperlipidemia. 
Methods: LDL receptor knock out mice (LDLR-‘-) were implanted with spironolactone (35 
mgJkg/day) or placebo pellets at 6 weeks while on high lipid chow (5-8 animals/group). At 
18 weeks, vasomotor responses were assessed in aortas, with measurement of time to 
thrombosis after photochemical carotid artery injury. Aldosterone infused animals served 
